NCT00300365View on ClinicalTrials.gov

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Metabolic Syndrome
Interventions
DRUG

Pioglitazone

Pioglitazone, initially 30 mg, then titrated to 45 mg/day

OTHER

Placebo

Pioglitazone placebo

DRUG

Niacin ER

Niacin ER 2.0 g/day

DRUG

Aspirin

asprin 325 mg/day

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Kos Pharmaceuticals
All Listed Sponsors
collaborator

Kos Pharmaceuticals

INDUSTRY

lead

University of Pennsylvania

OTHER